ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0645

Prevalence and Clinical Features of COVID-19 in a Large Cohort of 199 Patients with Sarcoidosis

Anne-Claire Desbois1, Cindy Marques1, Leila Lefèvre1, Serge Barmo1, Camille Lorenzo1, Mathilde Leclercq1, Gaëlle Leroux1, Chloé Comarmond1, Catherine Chapelon-Abric1, Fanny Domont1, David Saadoun1 and Patrice Cacoub1, 1AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, Paris, France

Meeting: ACR Convergence 2020

Keywords: , ,

Session Information

Date: Saturday, November 7, 2020

Title: Infection-related Rheumatic Disease Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To investigate the prevalence, clinical features and outcomes of coronavirus disease 2019 (COVID-19) among sarcoidosis patients.

Methods: We retrospectively collected clinical features, treatments and outcomes of COVID-19 in a cohort of patients with sarcoidosis followed in a single tertiary university hospital.

Results: Among 199 sarcoidosis patients [mean age 58.8 (±14) years, 86 (43.2%) men], 26 (13%) were diagnosed with COVID-19 [definite (n=7), probable (n=12) and possible (n=7)]. Twenty-four out of 26 patients (92%) had at least one comorbidity, and 11/26 (42%) had two or more comorbidities. Demographic and clinical features of patients COVID-19 positive were similar to those of sarcoidosis patients COVID-19 negative. The administration of hydroxychloroquine or immunosuppressant was not associated with the occurrence or the severity of COVID-19. Four out of 26 (15.4%) COVID-19 positive patients required admission to hospital and two of them died. Hospitalized patients [mean age of 61 (±11.5) years] were receiving higher doses of long-term treatment with corticosteroids than non-hospitalized patients; 4/4 had pulmonary and 2/4 cardiac involvement of sarcoidosis, and all one or more comorbidity.

Conclusion: The prevalence of COVID-19 in sarcoidosis is slightly higher to that of the general population. Almost half of the COVID-19 positive patients have two or more comorbidities and about 15% present a severe course.

Disclosure: A. Desbois, None; C. Marques, None; L. Lefèvre, None; S. Barmo, None; C. Lorenzo, None; M. Leclercq, None; G. Leroux, None; C. Comarmond, None; C. Chapelon-Abric, None; F. Domont, None; D. Saadoun, None; P. Cacoub, None.

To cite this abstract in AMA style:

Desbois A, Marques C, Lefèvre L, Barmo S, Lorenzo C, Leclercq M, Leroux G, Comarmond C, Chapelon-Abric C, Domont F, Saadoun D, Cacoub P. Prevalence and Clinical Features of COVID-19 in a Large Cohort of 199 Patients with Sarcoidosis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/prevalence-and-clinical-features-of-covid-19-in-a-large-cohort-of-199-patients-with-sarcoidosis/. Accessed .

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-clinical-features-of-covid-19-in-a-large-cohort-of-199-patients-with-sarcoidosis/